Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?
ESMO Open
.
2024 Oct 3;9(10):103936.
doi: 10.1016/j.esmoop.2024.103936.
Online ahead of print.
Authors
A Rizzo
1
,
A D Ricci
2
,
G Brandi
3
Affiliations
1
S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Electronic address: rizzo.alessandro179@gmail.com.
2
Medical Oncology Unit, National Institute of Gastroenterology, IRCCS S de Bellis Research Hospital, Castellana Grotte, Italy.
3
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.
PMID:
39366293
DOI:
10.1016/j.esmoop.2024.103936
No abstract available
Publication types
Letter